Navigen, Inc. is a Salt Lake City-based pharmaceutical discovery and development company.
Its early strategy was to source early-stage technologies from academia and advance them to IND-enabling studies using non-dilutive funding from grants, contracts, and corporate collaborations. The company has been successfully executed on that strategy, having raised approximately $40 MM in non-dilutive funding and advancing two of its programs to pre-IND studies with the goal of filing IND applications on both within 12-14 months.